<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358162</url>
  </required_header>
  <id_info>
    <org_study_id>09-0111</org_study_id>
    <secondary_id>N01AI80024C</secondary_id>
    <nct_id>NCT01358162</nct_id>
  </id_info>
  <brief_title>Phase IC Study of Safety and PK of SQ109 300mg Daily</brief_title>
  <official_title>A Phase 1C, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 300 mg of SQ109 Given Once Daily for 14 Days in Normal, Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Healthy male and female volunteers will be given SQ109 300mg daily for 14 days to assess the&#xD;
      safety and tolerability and pharmacokinetics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1C randomized, placebo controlled, double-blinded, in-patient trial of a&#xD;
      single oral dose of 300 mg of SQ109 given daily for 14 consecutive days to evaluate the&#xD;
      safety, tolerability and pharmacokinetics of SQ109 in normal healthy male and female subjects&#xD;
      18-45 years of age.&#xD;
&#xD;
      Each subject will receive 300 mg of SQ109 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; tolerability via: physical exams, color and visual acuity tests, funduscopic exams, neurological exams, vital signs, electrocardiograms, routine clinical labs (includes chemistry, hematology, coagulation and urinalysis data), and adverse events.</measure>
    <time_frame>Days 1-14, 16-18, 21 and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples prior to and following single/multiple doses: AUC(0-t): area under the concentration time curve to the last time with concentration greater than or equal to the validated limit of quantitation of the assay</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: AUC(0-infinity): area under the concentration time curve to infinity</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: AUC(0-24): area under the concentration time curve to 24 hours</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1, 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: t1/2: apparent terminal half-life</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1 &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: CL/F: apparent oral clearance</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1, 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Vz/F: apparent volume of distribution</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1, 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Cmin: observed minimum concentration</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Cavg: calculated average concentration during the dosing interval</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Tmax: Time of maximum concentration (Cmax)</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1, 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: AUC(0-tau) Area under the concentration time curve to the end of the dosing interval, 24 hours</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1, 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: RCmax: Accumulation ratio for Cmax estimated as Cmax (Day 14) / Cmax (Day 1)</measure>
    <time_frame>Before and after dosing on days 1-14. Serial PK after dosing on days 1 &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Tmin: Time to minimum concentration (Cmin)</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1, 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Linearity Index: AUC(0-tau) (Day 14) / AUC(0-infinity)(Day 1)</measure>
    <time_frame>Before and after dosing on days 1-14. Serial PK after dosing on days 1 &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: RAUC : Accumulation ratio for AUC estimated as AUC0-tau (Day 14)/ AUC(0-24)(Day 1)</measure>
    <time_frame>Before and after dosing on days 1-14. Serial PK after dosing on days 1 &amp; 14.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SQ109: Serial blood samples for measurement of plasma levels of SQ109 prior to and following single/multiple doses: Cmax: observed maximum concentration</measure>
    <time_frame>Before and after dosing on days 1-14, then on days 16-21 &amp; 28. Serial PK after dosing on days 1, 5, &amp; 14.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>SQ109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of SQ109, orally, given daily for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given orally, daily for 14 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given orally, daily for 14 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SQ109</intervention_name>
    <description>A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.</description>
    <arm_group_label>SQ109</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be 18 to 45 years of age (inclusive).&#xD;
&#xD;
          -  Subject must be a healthy male or female volunteer (i.e., hematology, coagulation,&#xD;
             clinical chemistries and urinalysis tests must be within study-defined ranges (See&#xD;
             Appendix B). Clinical tests must be performed within 28 days of receiving first dose&#xD;
             of study drug.&#xD;
&#xD;
          -  Body Mass Index (BMI) must be between 18 and 30 kg/m2 inclusive.&#xD;
&#xD;
          -  Subject must be Tuberculin Skin Test/Purified Protein Derivative (TST/PPD) negative&#xD;
             (within the previous 1 year) at Screening. The TST/PPD may be omitted if the subject&#xD;
             presents written evidence of having a negative test during the previous 12 months.&#xD;
&#xD;
          -  Subject must be able to give voluntary written informed consent before any study&#xD;
             related procedure is performed.&#xD;
&#xD;
          -  If female, has no childbearing potential or agrees to avoid becoming pregnant from the&#xD;
             day of screening through their entire participation in the trial (Day 28) by using one&#xD;
             of the following acceptable methods of birth control plus recommended use of a barrier&#xD;
             method (condom) by the male partner (even if vasectomized):&#xD;
&#xD;
               1. intrauterine contraceptive device; or&#xD;
&#xD;
               2. diaphragm in combination with contraceptive jelly, cream, or foam; or&#xD;
&#xD;
               3. spermicide; or&#xD;
&#xD;
               4. abstinence. Non-childbearing potential is defined as being post-menopausal for at&#xD;
                  least 2 years, status after bilateral tubal ligation for at least 1 year, status&#xD;
                  after bilateral oophorectomy or status after hysterectomy.&#xD;
&#xD;
        Hormonal contraceptives of any type or form (including oral, transdermal, vaginal or depot&#xD;
        preparations) will not be allowed during the study.&#xD;
&#xD;
          -  All female subjects of childbearing potential must have a negative serum pregnancy&#xD;
             test at screening and within 24 hours of the first dose of study product.&#xD;
&#xD;
          -  Male subjects must agree to use an acceptable barrier method for birth control&#xD;
             (abstinence or use of a condom with spermicide) from screening through Study Day 28&#xD;
             and advice and recommend use of additional birth control (as in criterion 6 above) to&#xD;
             female sex partners throughout the study.&#xD;
&#xD;
          -  Subject agrees not to donate blood during the study and up to 30 days after Study Day&#xD;
             28.&#xD;
&#xD;
          -  Subject agrees to comply with all study requirements, including clinic house rules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of clinically significant gastrointestinal, renal, hepatic, neurologic,&#xD;
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or&#xD;
             cardiovascular disease or any other condition which, in the opinion of the Principal&#xD;
             Investigator (PI), would jeopardize the safety of the subject or impact the validity&#xD;
             of the study results.&#xD;
&#xD;
          -  Subject has been on an abnormal diet during the 4 weeks preceding the study. Abnormal&#xD;
             diet is defined as a diet in which the subject has a significant change in eating&#xD;
             habits (e.g., liquid diet only) and an unbalanced diet (e.g., protein only, high fat,&#xD;
             low carbohydrate, etc.).&#xD;
&#xD;
          -  Subject has received an investigational drug in a clinical trial within 30 days prior&#xD;
             to study initiation.&#xD;
&#xD;
          -  Subject has used any OTC medication, including vitamins and herbal supplements, within&#xD;
             7 days prior to Day 1 of the study, unless in the opinion of the PI, the substance&#xD;
             would not likely impact on the conduct of this study, including PK of SQ109.&#xD;
&#xD;
          -  Subject has used any prescription medication within 14 days prior to Day 1 of the&#xD;
             study, or the use of hormonal preparations containing sex hormones within 30 days&#xD;
             prior to Day 1 of the study.&#xD;
&#xD;
          -  Subject has any current medical condition requiring treatment with medication, either&#xD;
             prescription or OTC.&#xD;
&#xD;
        Subject has been treated with any known CYP450 enzyme altering drugs such as azoles,&#xD;
        antifungals, barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days&#xD;
        prior to Day 1 of the study.&#xD;
&#xD;
          -  Subject has a positive blood screen for HIV, hepatitis B surface antigen (HBsAg), or&#xD;
             hepatitis C antibody and/or a positive history for alcohol abuse or dependence and/or&#xD;
             a positive serum ethanol or a positive urine screen for drugs of abuse (amphetamines,&#xD;
             barbiturates, benzodiazepines, cocaine metabolites, marijuana, opiates, phencyclidine&#xD;
             (PCP)).&#xD;
&#xD;
          -  Subject has a baseline QTcF interval &gt;450 msec (males) or &gt;470 msec (females) (defined&#xD;
             in Section 9.1.3) or a family history of prolonged QTcF syndrome or premature cardiac&#xD;
             death.&#xD;
&#xD;
          -  Subject has Wolf Parkinson White Syndrome (WPW) or family history of WPW or a history&#xD;
             of supra-ventricular tachycardias or syncope.&#xD;
&#xD;
          -  Subject has lived with a person having active TB or has traveled to an area of endemic&#xD;
             TB within the past 12 months.&#xD;
&#xD;
          -  Subject has an abnormal result on the Ishihara color test, the funduscopic exam,&#xD;
             current optic neuritis or known retinal disease.&#xD;
&#xD;
          -  Subject has an uncontrolled intercurrent illness (i.e., active infection) or fever&#xD;
             (oral temperature &gt;/=100 degrees F or &gt;/= 37.7 degrees C).&#xD;
&#xD;
          -  Subject has had major surgery within 4 weeks of study entry.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Subject has donated blood within the past 30 days prior to Day 1 of the study.&#xD;
&#xD;
          -  Subject has allergy to ethambutol or related compounds.&#xD;
&#xD;
          -  Subject is an employee of or family member of an employee of Sequella, Quintiles, or&#xD;
             DynPort Vaccine Company LLC (DVC).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quintiles Phase I Services - Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>May 10, 2013</last_update_submitted>
  <last_update_submitted_qc>May 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

